AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Biotech Firm Tiziana Life Sciences to Showcase Drug Candidate at Saudi Innovation Forum
ByAinvest
Tuesday, Sep 30, 2025 9:46 pm ET1min read
Tiziana Life Sciences has been invited to present at the Life Science Innovation Forum in Riyadh, Saudi Arabia. The conference aims to connect drug developers and research groups with investors and policymakers, supporting the country's National Biotechnology Strategy. The company will showcase its lead drug candidate, foralumab, a fully human anti-CD3 monoclonal antibody being developed as a nasal spray for neuroinflammation conditions.
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a clinical-stage biopharmaceutical company, has been invited to present at the 2025 Life Science Innovation Forum (LSIF) in Riyadh, Saudi Arabia. The event, scheduled for October 1-2, aims to connect drug developers and research groups with investors and policymakers, aligning with Saudi Arabia's National Biotechnology Strategy [1].Tiziana Life Sciences will showcase its lead drug candidate, foralumab, a fully human anti-CD3 monoclonal antibody. Foralumab is being developed as a nasal spray for neuroinflammation conditions, specifically Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS). The drug has shown promising results in clinical trials, with 14 patients in an open-label Expanded Access Program (EA) Program (NCT06802328) experiencing either an improvement or stability of disease within 6 months [2].
The LSIF 2025 will feature presentations from leading biotech companies, panel discussions, and networking sessions, facilitating investment, collaboration, and strategic partnerships. Tiziana Life Sciences' participation represents an opportunity to engage with global investors and explore potential collaborations to advance its mission of delivering next-generation immunotherapy solutions [1].
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet